With the advancement of delivery vectors and gene editing technologies, cell and gene therapies have been proven to be a very real and affordable solution to otherwise many untreatable diseases. It is now possible to add, silence, replace, and modify genes to treat diseases like neuromuscular disorders, immunodeficiencies, and ocular and liver diseases as well as develop enhanced cells for the treatment of diseases like cancer.
Although cell and gene therapies show great promise but the full extent of their clinical impact in the long term is not yet certain. Researchers and scientists from the past decades have been actively working on developing cell/gene-mediated innovative and promising solutions.
Achieving cost efficiency while developing an effective cell and gene therapy, still remains one of the major challenges to address. Several biotherapeutic companies are developing strategies to reduce cost and time. Various strategies such as single-use bioreactors, engineered vectors, and automating the vector design process are being recently utilized to significantly reduce manufacturing costs.
Ingenious e-Brain has prepared an exclusive syndicate report on the topic “Cost Reduction Technologies for Cell and Gene Therapies”, this report covers all the technologies being explored across different processes of upstream, downstream, packaging, and storage of cell and gene therapy products, opportunities for different type of players such as CGT manufacturers, CRO/CDMOs, raw material providers, tools and technology providers, and others along with an opportunity matrix and expert recommendations.
Ingenious e-Brain Solutions forecasts a considerable trend for the integration of AI/ML models in the designing and manufacturing of cell and gene therapy products. AI models and ML approaches can effectively accelerate the R&D for cell and gene therapies by saving time and avoiding the need to undertake unnecessary costly experiments. AI and advanced analytics are poised to become vital enablers for boosting the return on R&D spending in the cell and gene therapy value chain by increasing speed, reducing clinical failures, cutting costs across the manufacturing value chain, and enabling sustainable technology platforms.
Many leading players such as Roche, Bayer, and Novartis are incorporating the power of AI to analyse cellular and genetic data for developing therapeutic formulations in the domain. Various Start-Ups such as Dyno Therapeutics, Capsigen are effectively utilizing artificial intelligence for vector designing and engineering in the cell and gene therapy domain.